Sii Investments Inc. WI lowered its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,137 shares of the pharmaceutical company’s stock after selling 394 shares during the period. Sii Investments Inc. WI’s holdings in GlaxoSmithKline PLC were worth $999,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in GlaxoSmithKline PLC by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after buying an additional 4,935,900 shares during the last quarter. FMR LLC lifted its stake in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after buying an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans lifted its stake in GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock valued at $57,884,000 after buying an additional 1,371,490 shares during the last quarter. Bank of America Corp DE lifted its stake in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its stake in GlaxoSmithKline PLC by 22.7% in the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock valued at $194,521,000 after buying an additional 833,501 shares during the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-shares-sold-by-sii-investments-inc-wi/1608182.html.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.501% during trading on Wednesday, hitting $40.735. 2,518,419 shares of the stock were exchanged. The stock has a 50-day moving average of $39.94 and a 200 day moving average of $41.66. The stock has a market cap of $99.56 billion, a P/E ratio of 39.472 and a beta of 1.03. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. Equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.80%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.

Several analysts recently commented on the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, September 14th. TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Finally, Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.